Bioventix (LSE:BVXP)

Bioventix develops high-affinity sheep monoclonal antibodies for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Related Articles

• Monday, 25th February, 2019 | Paul Summers

  2 secret small-cap growth stocks I think you need to know about

  These market minnows have been quietly making their owners a lot of money. Paul Summers take a closer look. Read More »

• Saturday, 22nd December, 2018 | Robert Faulkner

  Why I think this top small-cap stock could make you a fortune

  If you’re looking for a company that could produce triple-digit returns then I’d check out this little known small-cap. Read More »

• Monday, 8th October, 2018 | Kevin Godbold

  A FTSE 100 dividend growth stock I’d buy today and one top performer I’d consider selling

  Why I’d recycle my profits from this small-cap into this evergreen FTSE 100 (INDEXFTSE: UKX) big-cap. Read More »

• Saturday, 4th November, 2017 | Harvey Jones

  Why I’d buy AstraZeneca plc over this soaring growth stock

  Harvey Jones says AstraZeneca plc (LON: AZN) could hit new peaks and put this biotechnology upstart in its place. Read More »

• Monday, 16th October, 2017 | Zach Coffell

  Should you buy this growth company after profits soar 40%?

  The market reacted negatively to this company's explosive profit growth today. One Fool takes a closer look. Read More »

• Tuesday, 10th October, 2017 | Edward Sheldon, CFA

  Why this small-cap stock could be the UK’s most exciting investment opportunity right now

  Edward Sheldon identifies a fast-growing small-cap biotech stock that he believes has considerable potential. Read More »

• Monday, 18th September, 2017 | Kevin Godbold

  These small-cap growth stocks could be millionaire-makers

  I think these two growers look set to advance further. Read More »

• Friday, 10th February, 2017 | Zach Coffell

  2 small-cap stocks I’d buy right now

  One Fool has found two compelling small-cap growth opportunities for your consideration. Read More »

• Monday, 17th October, 2016 | Peter Stephens

  Should you buy this stock after it reports a 27% rise in revenue?

  Is this company set to soar after positive results? Read More »

• Saturday, 17th October, 2015 | Dave Sullivan

  Why I’ve Shunned GlaxoSmithKline plc & AstraZeneca plc But Bought Bioventix plc & Tristel plc

  Why this Fool prefers Tristel plc (LON: TSTL) and Bioventix plc (LON: BVXP) over sector heavyweights GlaxoSmithKline plc (LON: GSK) and Astrazeneca plc (LON:... Read More »